SARPOGRELATE

SynDRA canonical compound SYN0002520 — structure-anchored drug synonym record

Clinical phase	Launched
Primary target(s)	HTR2A \| HTR2B \| HTR2C
Mechanism of action	serotonin receptor antagonist
Indication	angina pectoris \| atherosclerosis \| Buerger's disease \| diabetes mellitus \| Raynaud's disease
Disease area	cardiology \| endocrinology \| rheumatology

All known targets

anplag
MCI-9042
sarpogrelate hydrochloride
sarpogrelate HCl
Sarpogrelato
Sarpogrelate [INN]
Sarpogrelate (INN)
Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester
4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
sarpogrelato
sarpogrelatum
RefChem:181463
DTXCID2028303
UNII-19P708E787
NCGC00167489-01
NCGC00167489-03
SCHEMBL49197
GTPL210
SARPOGRELATE [WHO-DD]
orb1687669
SCHEMBL29703848
SCHEMBL30001082
CHEBI:135697
BDBM50093789
STK631325
AKOS005563803
NCGC00167489-02
DA-67415
FS157999
HY-10563
CS-0002654
LS-187,118
D08508
SBI-0653865.0001
T62374
L000858
SR-01000883998